List of Excipients in Branded Drug BUPRENORPHINE HYDROCHLORIDE

Generic Drugs Containing BUPRENORPHINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba Pharmaceutical Associates Inc and dba PAI Pharma	buprenorphine hydrochloride	0121-1019	ANHYDROUS CITRIC ACID
PAI Holdings LLC dba Pharmaceutical Associates Inc and dba PAI Pharma	buprenorphine hydrochloride	0121-1019	LACTOSE MONOHYDRATE
PAI Holdings LLC dba Pharmaceutical Associates Inc and dba PAI Pharma	buprenorphine hydrochloride	0121-1019	MANNITOL
PAI Holdings LLC dba Pharmaceutical Associates Inc and dba PAI Pharma	buprenorphine hydrochloride	0121-1019	POVIDONE K30
PAI Holdings LLC dba Pharmaceutical Associates Inc and dba PAI Pharma	buprenorphine hydrochloride	0121-1019	SODIUM STEARYL FUMARATE

What are the Most Frequently-Used Excipients in BUPRENORPHINE HYDROCHLORIDE?

# Of NDCs	Excipient
14	ANHYDROUS CITRIC ACID
5	ANHYDROUS DEXTROSE
1	DEXTROSE
6	HYDROCHLORIC ACID
1	LACTOSE

Buprenorphine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Buprenorphine hydrochloride has the strongest excipient-driven commercial opportunities in transmucosal films, buccal systems, abuse-deterrent products, and differentiated long-acting delivery. The active ingredient’s low oral bioavailability, bitter taste, high potency, and opioid-control requirements make formulation performance more important than simple tablet substitution. The most defensible opportunities combine mucoadhesion, rapid dissolution, dose uniformity, moisture control, palatability, and manufacturing barriers.

What pharmaceutical products contain buprenorphine hydrochloride?

Buprenorphine hydrochloride is used in oral transmucosal, buccal, and combination opioid-dependence products. Some injectable and transdermal products use buprenorphine in forms or delivery systems that do not rely on buprenorphine hydrochloride as the finished-product design driver.

Product	Manufacturer	Route	Active ingredient	Commercial formulation issue
Subutex	Indivior and generic manufacturers	Sublingual tablet	Buprenorphine hydrochloride	Rapid transmucosal absorption, taste, tablet disintegration
Suboxone	Indivior	Sublingual/buccal film	Buprenorphine hydrochloride and naloxone hydrochloride	Film adhesion, dose uniformity, diversion deterrence
Generic buprenorphine/naloxone	Multiple manufacturers	Sublingual tablet or film	Buprenorphine hydrochloride and naloxone hydrochloride	ANDA bioequivalence and formulation similarity
Belbuca	Bausch Health	Buccal film	Buprenorphine hydrochloride	Low-dose buccal delivery, adhesion, controlled release
Sublocade	Indivior	Subcutaneous depot injection	Buprenorphine	ATRIGEL depot system and injection-site performance
Brixadi	Braeburn	Subcutaneous extended-release injection	Buprenorphine	Long-acting depot technology and product differentiation

Subutex and Suboxone are primarily associated with opioid use disorder. Belbuca is indicated for chronic pain in patients requiring continuous, around-the-clock opioid treatment. FDA-approved labeling identifies buprenorphine hydrochloride as the active pharmaceutical ingredient in Subutex, Suboxone, and Belbuca products. (FDA, 2023a, 2023b, 2024)

Why does buprenorphine hydrochloride require a specialized excipient strategy?

Buprenorphine hydrochloride presents several formulation constraints:

1. It has high pharmacologic potency, so small absolute dose deviations can affect clinical exposure.
2. Conventional gastrointestinal administration produces limited systemic exposure because of extensive first-pass metabolism.
3. Sublingual and buccal products must overcome salivary washout and short mucosal residence time.
4. The drug has a pronounced bitter taste that can reduce adherence.
5. Combination products must maintain the required buprenorphine-to-naloxone ratio throughout manufacturing and dosing.
6. Opioid products face diversion, misuse, pediatric exposure, and accidental-ingestion risks.
7. Film and buccal systems are sensitive to humidity, packaging, polymer grade, and coating process conditions.

The commercial value therefore lies in controlling the drug’s delivery environment rather than merely improving powder flow or tablet hardness.

What excipients are used in buprenorphine hydrochloride products?

Sublingual tablet excipients

Buprenorphine hydrochloride sublingual tablets generally use conventional direct-compression or granulation excipients. Representative categories include:

• Lactose or another water-soluble diluent
• Mannitol for mouthfeel and compressibility
• Corn starch or other disintegrant
• Povidone as a binder
• Magnesium stearate as a lubricant
• Citric acid or another pH-modifying component

The formulation objective is rapid tablet breakup and dissolution under the tongue. Excessive hydrophobic lubricant, high compression force, or slow-wetting excipients can reduce dissolution and delay absorption.

A generic tablet developer has limited freedom if the product must match reference-product dissolution, assay, content uniformity, and pharmacokinetic performance. The most practical improvement areas are particle-size control, granulation endpoint, lubricant concentration, and taste-masking coating.

Sublingual and buccal film excipients

Film products typically use a polymer matrix with plasticizers, sweeteners, flavoring agents, colorants, and processing aids. Relevant excipient classes include:

Excipient class	Function	Key development risk
Film-forming polymer	Creates the dissolving or mucoadhesive matrix	Tensile strength, dissolution rate, residual solvent
Polyethylene oxide or cellulose derivative	Controls wetting, adhesion, and release	Viscosity drift and dose segregation
Polycarbophil or carbomer	Increases mucosal residence	Excessive swelling or mouthfeel
Plasticizer	Prevents brittleness	Migration, tackiness, stability
Sweetener	Reduces bitterness	Hygroscopicity and taste interaction
Flavoring agent	Improves acceptability	Volatility and batch consistency
pH modifier	Controls local microenvironment	Irritation and drug-release changes
Surfactant or wetting agent	Improves dissolution	Mucosal tolerance and regulatory scrutiny

Suboxone film uses a multilayered polymeric film approach that separates product performance from conventional tablet excipient architecture. The formulation and manufacturing process were central subjects in litigation involving Indivior’s film patents. (U.S. Patent Nos. 8,475,832, 8,603,514)

Belbuca uses a buccal film designed to adhere to the inner cheek and release buprenorphine hydrochloride over an extended period. Its commercial opportunity depends on sustained mucosal residence at relatively low dose strengths rather than the rapid dissolution profile used for opioid-dependence products. (FDA, 2024)

What excipient combinations are most commercially attractive?

1. Fast-dissolving sublingual films

A fast-dissolving film can compete with tablets through:

• Shorter in-mouth residence time
• Lower swallowing burden
• Improved dose portability
• Better dose concealment
• Reduced need for water
• More consistent patient handling

The formulation challenge is balancing rapid disintegration with adequate mechanical strength. A film that dissolves too quickly during manufacturing or handling may have poor packaging stability. A film that is too strong or hydrophobic may delay drug release.

Commercially attractive excipient combinations include a hydrophilic film former, a low-migration plasticizer, a high-intensity sweetener, and a controlled amount of mucoadhesive polymer. The strongest product profile is usually a thin film with low residual moisture, rapid dissolution, and minimal bitter aftertaste.

2. Abuse-deterrent buprenorphine/naloxone films

Buprenorphine/naloxone combinations are designed to reduce opioid misuse by combining buprenorphine’s therapeutic effect with naloxone’s antagonistic activity when the product is misused by injection. Excipient strategy can support the product’s abuse-deterrent profile through:

• Rapid oral dissolution but poor suitability for extraction
• Polymer networks that resist dose separation
• Limited solvent compatibility
• Controlled film thickness
• Strong unit-dose packaging
• Tamper-evident packaging and traceability

An abuse-deterrent claim requires product-specific evidence. Excipients alone do not establish abuse-deterrent labeling. FDA evaluates the complete dosage form, including manipulation, extraction, route-specific abuse testing, and clinical relevance. (FDA, 2015)

3. Buccal extended-release films

Belbuca establishes a differentiated market for low-dose buprenorphine hydrochloride delivered through a buccal system. Potential formulation improvements include:

• Longer adhesion without mucosal injury
• Lower variability caused by saliva and eating
• Better adhesion in patients with dry mouth
• Reduced bitterness during the release period
• Lower film thickness
• More consistent release across strength levels

A major technical opportunity is the development of a polymer system that maintains adhesion but limits excessive swelling. Carbomer, polycarbophil, cellulose derivatives, and polyethylene oxide can produce strong adhesion, but their concentrations must be controlled to avoid discomfort, delayed dissolution, or dose dumping.

4. Pediatric- and caregiver-friendly dosage forms

Buprenorphine is subject to serious pediatric exposure risk. A commercial product for supervised administration could use:

• Unit-dose child-resistant packaging
• Smaller films with clear strength differentiation
• Color or imprint systems that do not compromise dissolution
• Packaging that limits residual drug exposure
• Lower-contact handling for caregivers

A pediatric opportunity would require strong safety controls and a clear clinical rationale. The excipient profile would need to account for sweetener exposure, flavoring agents, mucosal tolerability, and accidental ingestion.

What patents protect buprenorphine hydrochloride formulations?

Patent protection is concentrated in dosage-form architecture, polymer composition, manufacturing methods, and therapeutic use rather than in the underlying buprenorphine molecule.

Protection category	Typical claim focus	Commercial effect
Film composition	Polymer matrix, drug distribution, multilayer construction	Can delay generic film entry
Manufacturing process	Casting, drying, solvent control, layer formation	Can create a process barrier even where composition claims are narrow
Buccal adhesion	Polymer combinations and residence time	Supports differentiated pain products
Combination formulation	Buprenorphine/naloxone ratio and film properties	Protects opioid-dependence products
Method of use	Opioid use disorder, induction, maintenance, pain	May limit label or carve-out strategies
Packaging and device	Unit-dose packaging, applicators, depot injection systems	Supports product handling and safety differentiation

Suboxone film patent disputes demonstrated that formulation patents can be commercially significant even after the active ingredient is long off patent. In Teva Pharmaceuticals USA, Inc. v. Indivior Inc., the Federal Circuit addressed the scope and validity of Indivior’s Suboxone film patent claims. The case involved written-description issues and claim scope for polymeric film formulations. (U.S. Court of Appeals for the Federal Circuit, 2020)

A generic company can avoid some method-of-use claims through a section viii label carve-out, but formulation and composition claims generally cannot be avoided by removing an indication. Paragraph IV certification remains the principal route for challenging listed patents where a generic applicant believes the patents are invalid, unenforceable, or not infringed.

What is the Orange Book status of buprenorphine hydrochloride products?

The Orange Book lists approved drug products and applicable patent and exclusivity information. The exact listing differs by reference product, dosage form, strength, and marketing status. Buprenorphine hydrochloride tablets and films have historically faced generic competition, while newer long-acting products have relied more heavily on formulation, delivery-system, device, and regulatory exclusivity. (FDA, 2025)

Product type	Generic-entry position	Main barrier
Buprenorphine sublingual tablet	Established generic market	Bioequivalence, manufacturing scale, state substitution rules
Buprenorphine/naloxone tablet	Established generic market	Ratio control, taste, dissolution, opioid-use labeling
Buprenorphine/naloxone film	More technically difficult	Film patents, content uniformity, process controls
Buccal buprenorphine film	Limited direct substitution	Mucoadhesion, release profile, dose proportionality
Long-acting injectable	High barrier	Depot technology, injection performance, device and clinical data

Subutex and early buprenorphine products no longer provide a strong small-molecule exclusivity position. Commercial protection instead depends on dosage form, manufacturing know-how, supply reliability, brand recognition, payer positioning, and clinical-use differentiation.

When does buprenorphine hydrochloride lose exclusivity?

The active molecule is long past basic compound patent exclusivity. The relevant commercial question is when each formulation and delivery system loses its remaining regulatory and patent protection.

Exclusivity timeline

Period	Market event
2002	FDA approval of Suboxone sublingual tablet for opioid dependence
2002	FDA approval of Subutex sublingual tablet
2010	FDA approval of Suboxone sublingual film
2015	FDA approval of Belbuca buccal film for chronic pain
2017	FDA approval of Sublocade extended-release injection
2018 onward	Expanded generic and litigation activity around buprenorphine/naloxone products
2023	FDA approval of Brixadi extended-release injection
2026	Newer injectable products remain more protected by delivery-system and regulatory barriers than by the buprenorphine molecule

Three-year exclusivity for a new dosage form or new clinical investigation can apply under the Hatch-Waxman framework when the approval is supported by sponsor-conducted clinical investigations. It does not provide the same barrier as new chemical entity exclusivity. Patent expiration dates must be evaluated patent by patent in the FDA Orange Book and relevant court records. (FDA, 2024; U.S. Code, 2024)

Which companies are challenging buprenorphine hydrochloride products?

The generic competitive field includes major manufacturers and specialty-generic companies with experience in controlled substances and oral films. Companies that have participated in the broader buprenorphine and buprenorphine/naloxone market include Teva, Mylan/Viatris, Dr. Reddy’s Laboratories, Sandoz, Hikma, Alvogen, and other ANDA sponsors.

Competition has focused on:

• Sublingual tablets
• Buprenorphine/naloxone tablets
• Buprenorphine/naloxone films
• Alternative strengths
• State substitution and pharmacy availability
• Hospital and public-sector contracting
• Treatment-program supply

A Paragraph IV challenger to a protected film product faces technical risks beyond patent litigation. FDA may require convincing evidence of film adhesion, dissolution, strength uniformity, extractables, residual solvents, and pharmacokinetic comparability.

How strong is the patent estate for buprenorphine hydrochloride?

The estate is weak for the active ingredient and conventional sublingual tablets, moderate for combination films, and stronger for buccal and long-acting delivery systems.

Product architecture	Patent strength	Reason
Plain sublingual tablet	Low	Mature technology and multiple generic suppliers
Buprenorphine/naloxone tablet	Low to moderate	Formulation and ratio claims may remain relevant
Buprenorphine/naloxone film	Moderate	Polymer-film patents and manufacturing know-how
Buprenorphine buccal film	Moderate to strong	Adhesion, release, strength, and process integration
Extended-release injectable	Stronger	Depot composition, delivery platform, injection characteristics, and clinical data

The strongest defensible position combines patent claims with difficult-to-copy process parameters. A narrow polymer claim is vulnerable if a competitor can substitute another film former. A broader commercial moat arises when the product requires a specific polymer ratio, drying profile, moisture window, thickness range, and pharmacokinetic performance.

What manufacturing and IP barriers affect commercial entry?

Manufacturing control is a major barrier in buprenorphine hydrochloride films. Critical process parameters include:

• Drug dispersion in the casting solution
• Polymer solution viscosity
• Solvent evaporation rate
• Film thickness
• Web speed
• Drying temperature
• Residual moisture
• Cutting accuracy
• Unit-dose content uniformity
• Packaging humidity protection

Controlled-substance manufacturing also requires DEA registration, inventory controls, diversion monitoring, security procedures, and validated reconciliation systems. These requirements raise the fixed cost of entry and favor established manufacturers.

For buccal films, the most valuable know-how may be outside the patent claims. Supplier-specific polymer grades, coating equipment, drying conditions, and packaging configurations can create a practical barrier that is difficult to reproduce through public patent disclosures.

What licensing deals and commercial partnerships are relevant?

Buprenorphine commercial opportunities have been structured through licensing, product-development, and technology-platform partnerships. The most important partnership targets are:

• Film technology owners
• Specialty controlled-substance manufacturers
• Contract development and manufacturing organizations
• Polymer and excipient suppliers
• Packaging companies with high-barrier unit-dose systems
• Long-acting injectable platform companies
• Treatment-program and government procurement channels

A licensing deal should distinguish between rights to the active ingredient, dosage form, manufacturing process, territory, regulatory dossier, and patent settlement. A film technology license without manufacturing scale or regulatory comparability data has limited value.

What generic launch scenarios exist for buprenorphine hydrochloride?

Scenario 1: Low-cost tablet entry

This is the lowest-risk strategy. A manufacturer enters with a conventional sublingual tablet, targets public programs and retail substitution, and competes on supply reliability and price.

Scenario 2: Film substitution

This strategy offers better patient handling and may capture prescriptions written for film. The principal risks are patent litigation, bioequivalence complexity, manufacturing yield, and packaging cost.

Scenario 3: Differentiated buccal film

A buccal film can target chronic pain and patients who cannot use conventional oral dosage forms. The commercial opportunity is narrower but has greater formulation defensibility.

Scenario 4: Long-acting delivery

Long-acting injectable products have higher development costs, clinical requirements, and manufacturing barriers. They compete on adherence, reduced dosing frequency, treatment-program economics, and diversion control rather than excipient cost.

How does buprenorphine hydrochloride compare with competing opioid-use-disorder products?

Product class	Main advantage	Main limitation	Excipient opportunity
Methadone tablets or solution	Low cost and established access	Diversion and daily administration	Taste, packaging, controlled dispensing
Buprenorphine tablets	Low cost and broad generic supply	Bitter taste and diversion risk	Rapid disintegration and taste masking
Buprenorphine/naloxone film	Portability and formulation differentiation	Higher manufacturing cost	Abuse deterrence and adhesion
Long-acting buprenorphine injection	Reduced dosing frequency	Injection cost and clinical logistics	Depot stability and injection comfort
Naltrexone injection	Non-opioid antagonist approach	Requires opioid-free induction	Suspension stability and injection usability

Key Takeaways

• Buprenorphine hydrochloride is commercially mature as an active ingredient but remains valuable in differentiated delivery systems.
• The strongest excipient opportunities are fast-dissolving films, abuse-deterrent buprenorphine/naloxone films, and mucoadhesive buccal systems.
• Tablet entry is price-driven and has limited patent defensibility.
• Film products face formulation, manufacturing, bioequivalence, and Paragraph IV risks.
• Buccal and long-acting products have stronger practical barriers because performance depends on polymer selection, process control, packaging, and clinical data.
• A competitive excipient strategy should prioritize mucosal residence, taste control, humidity stability, dose uniformity, and reproducible scale-up.
• Controlled-substance manufacturing, DEA compliance, and diversion controls materially affect commercial entry economics.
• The active ingredient no longer supplies meaningful basic-molecule exclusivity. Commercial value lies in dosage form, process, delivery platform, and regulatory execution.

Frequently Asked Questions

Can buprenorphine hydrochloride be formulated as a conventional oral tablet?

Yes. Conventional oral tablets are commercially established, but gastrointestinal delivery produces lower and more variable systemic exposure than sublingual or buccal administration.

Which excipient is best for buprenorphine hydrochloride taste masking?

No single excipient is universally preferred. A combination of sweetener, flavor system, pH control, and polymer-based taste masking is generally more effective than increasing sweetener concentration alone.

Are buprenorphine hydrochloride films difficult to manufacture?

Yes. Film thickness, drug dispersion, residual moisture, drying conditions, cutting accuracy, and packaging humidity can materially affect assay, dissolution, and content uniformity.

Can a generic company avoid buprenorphine film patents by using a different polymer?

Sometimes. A different polymer may avoid a composition claim, but the product can still face process, method-of-use, manufacturing, or equivalent-performance claims.

Is buprenorphine hydrochloride suitable for a sustained-release buccal product?

Yes. Belbuca demonstrates the feasibility of sustained buccal delivery. The main development risks are adhesion duration, local tolerability, release consistency, salivary effects, and dose proportionality.

References

1. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2023a). Suboxone buprenorphine hydrochloride and naloxone hydrochloride sublingual film prescribing information. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2023b). Subutex buprenorphine hydrochloride sublingual tablet prescribing information. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2024). Belbuca buprenorphine hydrochloride buccal film prescribing information. U.S. Department of Health and Human Services.

5. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

6. U.S. Court of Appeals for the Federal Circuit. (2020). Teva Pharmaceuticals USA, Inc. v. Indivior Inc., 18-1243.

7. U.S. Patent No. 8,475,832. (2013). Drug delivery system for buprenorphine and naloxone.

8. U.S. Patent No. 8,603,514. (2013). Pharmaceutical film compositions.

9. U.S. Code. (2024). 21 U.S.C. § 355: New drugs. Congress of the United States.